【洞察】达格列净二甲双胍缓释片属于口服降糖复方制剂我国市场竞争在不断加剧

Ofweek维科网2025-04-30

我国口服降糖药市场竞争激烈，二甲双胍、达格列净销售额位居前列。达格列净二甲双胍缓释片是一种新型口服降糖复方制剂，结合了达格列净及盐酸二甲双胍缓释片两种药物作用机制。达格列净为SGLT-2（钠－葡萄糖协同转运蛋白-2）抑制剂，通过抑制SGLT-2蛋白，减少肾脏重吸收葡萄糖，促进尿糖排泄，来达到降低血糖的目的。双胍类降糖药二甲双胍是目前治疗2型糖尿病（T2DM）的一线药物，双胍类降糖药属于胰岛素增敏剂...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2531770654?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-04-30 14:22","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2531770654","market":"us","top_or_hot":-1,"title":"【洞察】达格列净二甲双胍缓释片属于口服降糖复方制剂 我国市场竞争在不断加剧","media":"Ofweek维科网","content":"<div>\n<p>我国口服降糖药市场竞争激烈，二甲双胍、达格列净销售额位居前列。达格列净二甲双胍缓释片是一种新型口服降糖复方制剂，结合了达格列净及盐酸二甲双胍缓释片两种药物作用机制。达格列净为SGLT-2（钠－葡萄糖协同转运蛋白-2）抑制剂，通过抑制SGLT-2蛋白，减少肾脏重吸收葡萄糖，促进尿糖排泄，来达到降低血糖的目的。双胍类降糖药二甲双胍是目前治疗2型糖尿病（T2DM）的一线药物，双胍类降糖药属于胰岛素增敏剂...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430142221974b299c&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>【洞察】达格列净二甲双胍缓释片属于口服降糖复方制剂 我国市场竞争在不断加剧</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n【洞察】达格列净二甲双胍缓释片属于口服降糖复方制剂 我国市场竞争在不断加剧\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-30 14:22 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430142221974b299c&s=b><strong>Ofweek维科网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>我国口服降糖药市场竞争激烈，二甲双胍、达格列净销售额位居前列。达格列净二甲双胍缓释片是一种新型口服降糖复方制剂，结合了达格列净及盐酸二甲双胍缓释片两种药物作用机制。达格列净为SGLT-2（钠－葡萄糖协同转运蛋白-2）抑制剂，通过抑制SGLT-2蛋白，减少肾脏重吸收葡萄糖，促进尿糖排泄，来达到降低血糖的目的。双胍类降糖药二甲双胍是目前治疗2型糖尿病（T2DM）的一线药物，双胍类降糖药属于胰岛素增敏剂...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430142221974b299c&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2462157665.USD","symbol_name":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430142221974b299c&s=b","article_id":"2531770654","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430142221974b299c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2531770654","pubTimestamp":1745994136,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"达格列净二甲双胍缓释片是一种新型口服降糖复方制剂，结合了达格列净及盐酸二甲双胍缓释片两种药物作用机制。达格列净二甲双胍缓释片适用于2型糖尿病的治疗。复方制剂是口服降糖药市场新风口，近年来，我国市场规模逐年增长，达格列净二甲双胍缓释片作为新型口服降糖复方制剂，市场发展前景好。目前达格列净二甲双胍缓释片市场已吸引一大批企业布局，未来国产仿制药将逐渐侵蚀进口原研药市场份额。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","AZN":"阿斯利康","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU1829250122.USD":"高盛欧洲核心股票组合Acc","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4007":"制药","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","BK4568":"美国抗疫概念","BK4585":"ETF&股票定投概念","BK4588":"碎股","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC"},"translate_title":"[Insight] Dapagliflozin and metformin sustained-release tablets are oral hypoglycemic compound preparations, and competition in my country's market is intensifying","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":0.9},"content_text":"我国口服降糖药市场竞争激烈，二甲双胍、达格列净销售额位居前列。达格列净二甲双胍缓释片是一种新型口服降糖复方制剂，结合了达格列净及盐酸二甲双胍缓释片两种药物作用机制。达格列净为SGLT-2（钠－葡萄糖协同转运蛋白-2）抑制剂，通过抑制SGLT-2蛋白，减少肾脏重吸收葡萄糖，促进尿糖排泄，来达到降低血糖的目的。双胍类降糖药二甲双胍是目前治疗2型糖尿病（T2DM）的一线药物，双胍类降糖药属于胰岛素增敏剂，通过减少肝脏葡萄糖的输出来降低血糖。达格列净二甲双胍缓释片由达格列净和二甲双胍成分组成，两者药物机制互补，可以提供更持久、高效的血糖控制能力，减少患者服药片数、提高患者依从性。达格列净二甲双胍缓释片适用于2型糖尿病的治疗。糖尿病是一种内分泌代谢性疾病，近年来，由于人口老龄化、饮食习惯改变，全球糖尿病发病率和患病率均呈上升态势，我国糖尿病患者规模位居全球首位，现成年糖尿病患者达1.5亿人左右，口服降糖药市场需求空间广阔。我国口服降糖药市场竞争激烈，二甲双胍、达格列净销售额位居前列。近年来，口服降糖复方制剂作为降糖市场新风口，市场规模逐年增长，尤其是二甲双胍+其他口服降糖药，如达格列净二甲双胍缓释片、恒格列净二甲双胍缓释片、二甲双胍恩格列净片、二甲双胍格列本脲胶囊等。根据新思界产业研究中心发布的《2025-2029年中国达格列净二甲双胍缓释片市场行情监测及未来发展前景研究报告》显示，达格列净二甲双胍缓释片原研企业为阿斯利康，2014年获FDA批准上市，2023年6月获得NMPA批准，同年被纳入乙类《医保目录》。根据阿斯利康数据显示，2023年达格列净二甲双胍缓释片全球市场销售量约20亿片、销售额约16亿美元。目前达格列净二甲双胍缓释片专利尚未到期，但基于其前景，国内包括上海宣泰医药、正大天晴、齐鲁制药、石家庄四药、北京福元、华海药业等企业均提交了达格列净二甲双胍缓释片上市申请，十余家仿制药企业登记了生物等效实验。其中上海宣泰医药提交的3类仿制药达格列净二甲双胍缓释片于2024年9月获批上市，成为国内该品种的首家获批的仿制药企业。新思界行业分析人士表示，我国是全球糖尿病患病人数最多、发病率较高的国家，口服降糖药市场发展空间广阔。复方制剂是口服降糖药市场新风口，近年来，我国市场规模逐年增长，达格列净二甲双胍缓释片作为新型口服降糖复方制剂，市场发展前景好。目前达格列净二甲双胍缓释片市场已吸引一大批企业布局，未来国产仿制药将逐渐侵蚀进口原研药市场份额。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2531770654","isCrawlerRequest":true}

【洞察】达格列净二甲双胍缓释片属于口服降糖复方制剂 我国市场竞争在不断加剧

精彩评论

【洞察】达格列净二甲双胍缓释片属于口服降糖复方制剂我国市场竞争在不断加剧